<DOC>
	<DOCNO>NCT00670410</DOCNO>
	<brief_summary>Neuroblastoma malignant tumor sympathetic nervous system . It second common malignant tumor childhood . Although modest advance make past 20 year child high-risk neuroblastoma continue unsatisfactory long-term survival . This study administer induction chemotherapy follow high-dose ( myeloablative ) chemotherapy autologous stem cell transplantation , follow radiation therapy , immunotherapy non myeloablative allogeneic stem cell transplant treatment neuroblastoma . The purpose clinical research trial study feasibility give immunotherapy non-myeloablative allogeneic transplant ( NAT/AlloSCT ) , follow myeloablative therapy autologous stem cell transplant ( MAT/AutoSCT ) . This study also determine side effect well response rate group patient ( treatment arm ) .</brief_summary>
	<brief_title>Autologous Transplant Followed Allogeneic Transplant High Risk Neuroblastoma</brief_title>
	<detailed_description>Despite modest advance make past two decade addition intensive chemotherapy high dose myeloablative therapy allogeneic autologous bone marrow transplantation , child high-risk neuroblastoma continue unsatisfactory long-term survival . The current survival child &gt; 1 year age diagnosis stage 4 neuroblastoma 20-35 % 1,7 . The overall treatment plan high-risk patient neuroblastoma : Induction Therapy Intensive induction chemotherapy cardioprotectant dexrazoxane ( Zinecard ) , vincristine , doxorubicin ( Adriamycin ) , cyclophosphamide ( ZVAC ) , alternate cisplatin etoposide ( CiE ) . Patients receive induction chemotherapy alternate protocol achieve CR , VGPR , PR also eligible entry receive consolidation therapy AlloSCT immunotherapy discussion approval Principal Investigators ) . Consolidation Therapy AutoSCT Consolidation therapy myeloablative preparative regimen carboplatin , thiotepa , topotecan ( CaTT ) follow AutoSCT PBSCs ( CD34+ selection optional ) . Immunotherapy Non-myeloablative AlloSCT Immunotherapy non-myeloablative preparative regimen busulfan fludarabine follow AlloSCT either : ( Arm A ) relate donor ( 5/6 6/6 HLA match ) ; ( Arm B ) umbilical cord blood donor ( unrelated 4/6 , 5/6 , 6/6 HLA match , related 3/6 , 4/6 , 5/6 , 6/6 HLA match ) . Patients umbilical cord blood donor also receive Thymoglobulin ( ATG-rabbit ) preparative regimen . GVHD prophylaxis consist Tacrolimus mycophenolate mofetil ( MMF ) . Maintenance Therapy Patients related donor persistent disease detect prior NAT/AlloSCT assign Arm A1 receive two course DLI , follow cis-RA 6 cycle . Patients related donor persistent disease detect prior NAT/AlloSCT assign Arm A2 receive cis-RA 6 cycle . Patients umbilical cord blood donor receive cis-RA 6 cycle . Radiation Therapy Due potential risk increase GVHD follow radiation therapy , local radiation therapy primary tumor site ( 21 Gy ) metastatic site , give NAT/AlloSCT patient Arm A2 Arm B , prior cis-RA therapy . Radiation therapy give follow DLI Arm A1 , prior cis-RA therapy .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age &lt; 30 year age time initial diagnosis . Patients must diagnosis neuroblastoma ( ICDO morphology 9500/3 ) verify histology and/or demonstration clump tumor cell bone marrow elevate urinary catecholamine metabolite . Patients follow disease stage diagnosis eligible , meet specified criterion . The revised International Neuroblastoma Staging System ( INSS ) use stage patient 58 . ( See 14.3 risk assignment ) . Patients newly diagnose neuroblastoma age &gt; 547 day follow : INSS Stage 4 neuroblastoma regardless biologic factor INSS Stage 2A/2B MYCN amplification ( &gt; 10 ) INSS Stage 3 MYCN amplification ( &gt; 10 ) OR Unfavorable histology Patients newly diagnose neuroblastoma age &lt; 365 day follow : * INSS Stage 3 , 4 , OR 4S neuroblastoma AND MYCN amplification ( &gt; 10 ) . Patients newly diagnose Neuroblastoma age 365 &lt; 547 day follow : INSS Stage 3 MYCN amplification ( &gt; 10 ) INSS Stage 4 MYCN amplification ( &gt; 10 ) OR deoxyribonucleic acid ( DNA ) Index ( ploidy ) = 1 OR Unfavorable histology Patients &gt; 365 day INSS Stage 1 , 2 , 4S progress Stage 4 . Newly Diagnosed patient enter study within 4 week diagnosis , receive one cycle intermediate dose chemotherapy patient initially treat on/according low intermediate risk Children 's Oncology Group ( COG ) neuroblastoma study , within 4 week progression Stage 4 INSS Stage 1 , 2 , 4S . Patients treat alternative induction regimen and/or consolidation regimen ( AutoSCT ) enrol diagnosis achieve complete response ( CR ) , good partial response ( VGPR ) , partial response ( PR ) , minimal response ( MR ) meet criterion eligible either consolidation MAT/AutoSCT NAT/AlloSCT immunotherapy NAT/AlloSCT , ever clinically appropriate discussion Principal Investigators . Liver Function : alanine aminotransferase ( ALT ) bilirubin &lt; 3x normal Cardiac Function : Shortening fraction &gt; 27 % , ejection fraction &gt; 47 % , clinical congestive heart failure . Renal Function : Creatinine clearance and/or glomerular filtration rate ( GFR ) &gt; 60 ml/min/1.73m2 . Hematologic Function : Patients must adequate hematopoietic function ( absolute neutrophil count ( ANC ) &gt; 1000/mm3 platelet &gt; 100,000/mm3 ) unless inadequate hematopoiesis document due bone marrow involvement tumor ( &gt; 10 % tumor infiltration ) . Patients pregnant . Patients childbearing potential must practice effective method birth control participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Autologous Transplant</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>